PROK
Price
$1.54
Change
+$0.08 (+5.48%)
Updated
Dec 20, 04:59 PM (EDT)
100 days until earnings call
RNA
Price
$31.82
Change
+$0.77 (+2.48%)
Updated
Dec 20 closing price
71 days until earnings call
Ad is loading...

PROK vs RNA

Header iconPROK vs RNA Comparison
Open Charts PROK vs RNABanner chart's image
ProKidney
Price$1.54
Change+$0.08 (+5.48%)
Volume$3.98K
CapitalizationN/A
Avidity Biosciences
Price$31.82
Change+$0.77 (+2.48%)
Volume$2.93M
CapitalizationN/A
PROK vs RNA Comparison Chart
Loading...
PROK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PROK vs. RNA commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PROK is a Hold and RNA is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (PROK: $1.51 vs. RNA: $31.82)
Brand notoriety: PROK and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PROK: 297% vs. RNA: 249%
Market capitalization -- PROK: $196.43M vs. RNA: $3.8B
PROK [@Biotechnology] is valued at $196.43M. RNA’s [@Biotechnology] market capitalization is $3.8B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PROK’s FA Score shows that 0 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • PROK’s FA Score: 0 green, 5 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, RNA is a better buy in the long-term than PROK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PROK’s TA Score shows that 3 TA indicator(s) are bullish while RNA’s TA Score has 4 bullish TA indicator(s).

  • PROK’s TA Score: 3 bullish, 5 bearish.
  • RNA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both PROK and RNA are a bad buy in the short-term.

Price Growth

PROK (@Biotechnology) experienced а -15.88% price change this week, while RNA (@Biotechnology) price change was -2.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

PROK is expected to report earnings on Apr 01, 2025.

RNA is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($3.8B) has a higher market cap than PROK($196M). RNA YTD gains are higher at: 251.602 vs. PROK (-15.169). PROK has higher annual earnings (EBITDA): -131.07M vs. RNA (-322.04M). RNA has more cash in the bank: 1.59B vs. PROK (407M). PROK has less debt than RNA: PROK (6.44M) vs RNA (7.6M). RNA has higher revenues than PROK: RNA (10.1M) vs PROK (0).
PROKRNAPROK / RNA
Capitalization196M3.8B5%
EBITDA-131.07M-322.04M41%
Gain YTD-15.169251.602-6%
P/E RatioN/AN/A-
Revenue010.1M-
Total Cash407M1.59B26%
Total Debt6.44M7.6M85%
TECHNICAL ANALYSIS
Technical Analysis
PROKRNA
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bearish Trend 3 days ago
58%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
63%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 3 days ago
87%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
56%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Ad is loading...
PROK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ABRWX17.800.28
+1.60%
DSS AmericaFirstMonthlyRisk-OnRisk-Off I
ETIHX33.680.48
+1.45%
Eventide Healthcare & Life Sciences I
GMYPX16.720.18
+1.09%
Goldman Sachs Large Cap Value P
ODIIX127.571.07
+0.85%
Invesco Discovery R6
JHJCX22.03-1.98
-8.25%
JHancock ESG Large Cap Core C

PROK and

Correlation & Price change

A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RXRX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROK
1D Price
Change %
PROK100%
+3.42%
RXRX - PROK
37%
Loosely correlated
-0.99%
PRME - PROK
34%
Loosely correlated
+3.94%
BEAM - PROK
33%
Poorly correlated
+8.04%
ADPT - PROK
32%
Poorly correlated
+6.50%
RNA - PROK
32%
Poorly correlated
+2.48%
More